A preoperative serum signature of CEA+/CA125+/CA19‐9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
Authors:
Open Access
- 1 October 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 136 (9) , 2216-2227
Abstract
Pancreatectomy is associated with significant morbidity and unpredictable outcome, with few diagnostic tools to determine, which patients gain the most benefit from this treatment, especially before the operation. This study aimed to define a preoperative signature panel of serum markers to indicate response to pancreatectomy for pancreatic cancer. Over 1000 patients with pancreatic cancer treated at two independent high‐volume institutions were included in this study and were divided into three groups, including resected, locally advanced and metastatic. Eight serum tumor markers most commonly used in gastrointestinal cancers were analyzed for patient outcome. Preoperative CA19‐9 independently indicated surgical response in pancreatic cancer. Patients with CA19‐9 ≥1000 U/mL generally had a poor surgical benefit. However, a subset of these patients still achieved a survival advantage when CA19‐9 levels decreased postoperatively. CEA and CA125 in the presence of CA19‐9 ≥1000 U/mL could independently predict the non‐decrease of CA19‐9 postoperatively. The combination of the three markers was useful for predicting a worse surgical outcome with a median survival of 5.1 months vs. 23.0 months (p < 0.001) for the training cohort and 7.0 months vs. 18.2 months (p < 0.001) for the validation cohort and also suggested a higher prevalence of early distant metastasis after surgery. Resected patients with this proposed signature showed no survival advantage over patients in the locally advanced group who did not receive pancreatectomy. Therefore, a preoperative serum signature of CEA+/CA125+/CA19‐9 ≥1000 U/mL is associated with poor surgical outcome and can be used to select appropriate patients with pancreatic cancer for pancreatectomy.Keywords
This publication has 32 references indexed in Scilit:
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative TherapyAnnals of Surgical Oncology, 2012
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- Pathobiological Implications of MUC16 Expression in Pancreatic CancerPLOS ONE, 2011
- Arterial en bloc resection for pancreatic carcinomaBritish Journal of Surgery, 2011
- Activation of β-Catenin by Hypoxia in Hepatocellular Carcinoma Contributes to Enhanced Metastatic Potential and Poor PrognosisClinical Cancer Research, 2010
- Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic CancerGastroenterology, 2009
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Extended Resection for Pancreatic AdenocarcinomaThe Oncologist, 2007
- Surgery for Recurrent Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2007
- Assessment of Complications After Pancreatic SurgeryAnnals of Surgery, 2006